RVMD vs. ONC, TEVA, SMMT, GMAB, ITCI, VTRS, MRNA, RDY, PCVX, and SRPT
Should you be buying Revolution Medicines stock or one of its competitors? The main competitors of Revolution Medicines include Beigene (ONC), Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), Genmab A/S (GMAB), Intra-Cellular Therapies (ITCI), Viatris (VTRS), Moderna (MRNA), Dr. Reddy's Laboratories (RDY), Vaxcyte (PCVX), and Sarepta Therapeutics (SRPT). These companies are all part of the "pharmaceutical products" industry.
Revolution Medicines vs.
Beigene (NASDAQ:ONC) and Revolution Medicines (NASDAQ:RVMD) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, community ranking, analyst recommendations, institutional ownership, media sentiment, risk and valuation.
Revolution Medicines has a consensus price target of $66.25, suggesting a potential upside of 56.83%. Given Revolution Medicines' stronger consensus rating and higher probable upside, analysts clearly believe Revolution Medicines is more favorable than Beigene.
Revolution Medicines received 91 more outperform votes than Beigene when rated by MarketBeat users.
In the previous week, Beigene and Beigene both had 3 articles in the media. Beigene's average media sentiment score of 0.50 beat Revolution Medicines' score of 0.46 indicating that Beigene is being referred to more favorably in the media.
48.6% of Beigene shares are owned by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are owned by institutional investors. 7.4% of Beigene shares are owned by insiders. Comparatively, 8.0% of Revolution Medicines shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Revolution Medicines has lower revenue, but higher earnings than Beigene. Beigene is trading at a lower price-to-earnings ratio than Revolution Medicines, indicating that it is currently the more affordable of the two stocks.
Beigene has a beta of 0.63, indicating that its share price is 37% less volatile than the S&P 500. Comparatively, Revolution Medicines has a beta of 1.45, indicating that its share price is 45% more volatile than the S&P 500.
Revolution Medicines has a net margin of 0.00% compared to Beigene's net margin of -25.94%. Beigene's return on equity of -25.12% beat Revolution Medicines' return on equity.
Summary
Revolution Medicines beats Beigene on 13 of the 17 factors compared between the two stocks.
Get Revolution Medicines News Delivered to You Automatically
Sign up to receive the latest news and ratings for RVMD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Revolution Medicines Competitors List
Related Companies and Tools
This page (NASDAQ:RVMD) was last updated on 2/21/2025 by MarketBeat.com Staff
